Funding

California-Based Renata Medical Raises $25M in Series D Funding

Aug 20, 2026 | By Devin Jacobs

SUMMARY

Renata Medical raised $25M in Series D funding.
The funding will support expansion and clinical research.
Renata Medical develops heart devices for children.

Renata Medical, a Newport Beach, CA-based medical technology company dedicated to improving care for children with congenital heart disease (CHD), has raised $25 million in a Series D financing Round led by ARCHIMED.

The company will use the funding to expand commercialization of its Minima Stent System in the US, enter international markets, advance its pediatric CHD technology pipeline, and generate additional clinical evidence.

Funding Snapshot

Metric	Details
Fundraise Amount	$25 Million
Funding Stage	Series D
Lead Investor	ARCHIMED
Company	Renata Medical
Sector	MedTech / Pediatric Cardiology
Headquarters	Newport Beach, California, US
Key Product	Minima™ Stent System

RECOMMENDED FOR YOU

[Funding News] CA-based TrackLight Raises $3M Seed Funding

Team SR

Jun 25, 2024

Funding

Reju Receives €135M From Dutch NIKI Program

Startuprise

Apr 5, 2026

Funding

HighGround Raises $6.5M in Seed Funding Led by Next Frontier Capital

Devin Jacobs

Jun 18, 2026

About Renata Medical

Founded in 2019 by Dustin Armer and Eason Abbott, Renata Medical develops cardiovascular devices specifically designed to address unmet medical needs in pediatric patients.

The company focuses on creating, manufacturing, and commercializing technologies for children with congenital heart disease, with an emphasis on devices designed around the unique clinical needs of neonates, infants, and young children.

Core offerings include:

Pediatric cardiovascular devices
Congenital heart disease technologies
Growth stent systems
Pediatric specific cardiac solution's

Core Technologies / Products / Services

Capability/Product	Application/Use Case
Minima™ Stent System	Treats pulmonary artery stenosis and coarctation of the aorta
Growth Stent Technology	Designed to accommodate the growth of young patients
Pediatric Cardiovascular Devices	Addresses unmet needs in children's heart care
Clinical Evidence Programs	Supports evaluation and adoption of pediatric technologies

Leadership Comments

"Adoption of the Minima Stent System has exceeded our expectations since commercial launch in 2024, said Dustin Armer, Co-founder and Chief Executive Officer of Renata Medical.

"Children born with congenital heart defects have too often been treated with devices built for adults and many face repeat procedures simply because their implants cannot grow with them" said André-Michel Ballester, Managing Partner at ARCHIMED and former CEO of LivaNova.